{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:23:52Z","timestamp":1789604632105,"version":"build-2803163510"},"reference-count":27,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2012,9,25]],"date-time":"2012-09-25T00:00:00Z","timestamp":1348531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold>Focal hyperhidrosis can severely affect quality of life. So far, knowledge on the effect of systemic therapy of focal hyperhidrosis is limited.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold>To assess the efficacy and safety of methantheline bromide (MB) in the treatment of axillary and palmar\u2010axillary hyperhidrosis.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold>A multicenter controlled randomized double\u2010blind clinical trial was conducted in patients with axillary or palmar\u2010axillary hyperhidrosis defined by a sweat production &gt;50\u2003mg\/5\u2003min. Patients received 3\u2003\u00d7\u200350\u2003mg MB daily or placebo over a period of 28\u2003\u00b1\u20031\u2003days. Main outcome criterion was the reduction of sweat as measured by gravimetry on day 28\u2003\u00b1\u20031. Quality of life was assessed by Dermatology Life Quality Index (DLQI) and Hyperhidrosis Disease Severity Score (HDSS).<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold>A total of 339 patients were randomly assigned to receive MB or placebo. On day 28\u2003\u00b1\u20031, the mean axillary sweat production was 99\u2003mg for MB and 130\u2003mg for placebo compared with 168\u2003mg and 161\u2003mg respectively at baseline (<jats:italic>P\u2003<\/jats:italic>=\u20030.004). Patient\u2032s HDSS score decreased in the MB group from 3.2 to 2.4 compared with 3.2 to 2.7 for placebo (<jats:italic>P\u2003<\/jats:italic>=\u20030.002). Similar results could be obtained for the DLQI with 9.7 for MB and 12.2 for placebo, which decreased from 16.4 or 17 respectively (<jats:italic>P\u2003<\/jats:italic>=\u20030.003). Tolerability was good for both groups. The most frequent adverse event was dry mouth.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold>Fifty milligrams methantheline bromide three times a day is an effective and safe treatment of axillary hyperhidrosis.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2012.04708.x","type":"journal-article","created":{"date-parts":[[2012,9,25]],"date-time":"2012-09-25T20:19:46Z","timestamp":1348604386000},"page":"1278-1284","source":"Crossref","is-referenced-by-count":45,"title":["Efficacy and safety of methantheline bromide (Vagantin<sup>\u00ae<\/sup>) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo\u2010controlled trial"],"prefix":"10.1111","volume":"27","author":[{"given":"C.","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Berensmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Dirschka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Rzany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,9,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2007.06409.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.02.038"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.12.040"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06317.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.01.009"},{"key":"e_1_2_6_7_2","first-page":"870","article-title":"Focal hyperhidrosis: disease characteristics and treatments","volume":"5","author":"Campanelli A","year":"2009","journal-title":"Rev Med Suisse"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0007-1323.2001.02017.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008968401068"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.01.035"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000092285"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04173.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-195601000-00011"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0022-3565(25)32824-7","article-title":"Histamine H2\u2010receptor antagonism by propantheline and derivatives","volume":"219","author":"Hough LB","year":"1981","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_15_2","first-page":"CD004193","article-title":"Anticholinergics for urinary symptoms in multiple sclerosis","author":"Nicholas RS","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.3030420910"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0353.2004.04765.x"},{"key":"e_1_2_6_18_2","first-page":"303","article-title":"[Effect of bornaprine in localized hyperhidrosis]","volume":"15","author":"Castells Rodellas A","year":"1987","journal-title":"Med Cutan Ibero Lat Am"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.avsg.2011.06.007"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2009.00946.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1117\/1.3555183"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000119004"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2494.2010.00596.x"},{"key":"e_1_2_6_24_2","first-page":"16","article-title":"Correlation between Dermatology Life Quality Index and Minor test and differences in their levels over time in patients with axillary hyperhidrosis treated with botulinum toxin type A","volume":"19","author":"Skroza N","year":"2011","journal-title":"Acta Dermatovenerol Croat"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03880.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X74899"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2011.07.002"},{"key":"e_1_2_6_28_2","article-title":"Relative bioavailability and pharmacodynamic effects of methantheline compared with atropine in healthy subjects","author":"M\u00fcller C","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2012.04708.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2012.04708.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:44:37Z","timestamp":1744199077000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2012.04708.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,25]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1111\/j.1468-3083.2012.04708.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04708.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,25]]}}}